Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F114 - Biologic Therapy in Dermatology Beyond Psoriasis

Sunday, February 18; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Compare the different biologic treatments for atopic dermatitis, pemphigus and hidradenitis suppurativa
  • Evaluate the efficacy of biologics in atopic dermatitis, pemphigus and hidradenitis suppurativa
  • Select the best option for the treatment of atopic dermatitis, pemphigus and hidradenitis suppurativa

Description

The session will begin with a thorough discussion with the use of biologics in atopic dermatitis. This will be followed by a lecture on the use of Rituximab in pemphigus. The lecture to follow will overview biologics commonly used in rheumatoid arthritis with emphasis on dermatologic implications. The last lecture will summarize the biologic experience in hidradenitis suppurativa.

Disclosures

  • Blauvelt, Andrew, MD: AbbVie – A(H), C(H), I(Fees); Aclaris Therapeutics Inc. – A(H), C(H), I(Fees); Akros Pharma, Inc. – A(H), C(H); Allergan, Inc – A(H), C(H), I(Fees); Almirall – A(H), C(H); Amgen – A(H), C(H), I(Fees); Boehringer Ingelheim – A(H), C(H), I(Fees); Celgene – A(H), C(H), I(Fees); Dermavant Sciences – A(H), C(H), I(Fees); Dermira – A(H), C(H), I(Fees); Eli Lilly and Company – A(H), C(H), I(Fees); Galderma Laboratories, L.P. – A(H), C(H); Genentech, Inc. – A(H), C(H), I(Fees); GlaxoSmithKline – A(H), C(H), I(Fees); Janssen-Ortho Inc. – A(H), C(H), I(Fees), SP(H); Leo Pharma Inc – A(H), C(H), I(Fees); Meiji Seika Pharma Co., Ltd – A(H), C(H); Merck & Co., Inc – A(H), C(H), I(Fees); Novartis Pharmaceuticals Corp. – A(H), C(H), I(Fees); Pfizer Inc. – A(H), C(H), I(Fees); Purdue Pharma – A(H), C(H); Regeneron – A(H), C(H), I(Fees), SP(H); Sandoz, a Novartis company – A(H), C(H), I(Fees); Sanofi – A(H), C(H), SP(H); Sienna Biopharmaceuticals – A(H), C(H), I(Fees); Sun Pharmaceutical Industries Ltd. – A(H), C(H); UCB – A(H), C(H), I(Fees); Valeant Pharmaceuticals International – A(H), C(H), I(Fees); Vidac Pharma – A(H), C(H), I(Fees);
  • Kerdel, Francisco, MD: AbbVie – SP(H); Amgen – SP(H); Astellas Pharma US, Inc – A(H); Celgene Corporation – I(H); Eisai Pharmaceuticals – SP(H); Eli Lilly and Company – SP(H); Janssen Biotech – I(H); Novartis – SP(H); Pfizer Inc. – SP(H); Regeneron – SP(H); Sanofi – SP(H); Stiefel a GSK company – I(H);
  • Murrell, Dedee F., MD: 3M Pharmaceuticals – C(Grants/Research Funding); Abbott Laboratories – A(H), SP(H); AbbVie – I(Grants/Research Funding); Actavis – Speaker/Faculty Education(H); Almirall – C(H); Amgen – I(Fees); Amicus Therapeutics – A(H); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Ascent Pharmaceuticals – SP(H); Castle Creek Pharmaceuticals – C(Fees); CSL – SP(Grants/Research Funding), SP(H); Delfin Technology – I(EQ); Eli Lilly and Company – A(H); Galderma Laboratories, L.P. – I(Grants/Research Funding), I(OB); Janssen-Ortho Inc. – O(Grants/Research Funding); Leo Pharma Inc – Speaker/Faculty Education(H); Medimmune – I(Grants/Research Funding); Merck Serono – I(Fees), I(Grants/Research Funding); Molynlycke – SP(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – SP(H); Principia Biopharma Inc – C(H); Roche Laboratories – A(H), I(Grants/Research Funding); Samumed, LLC – I(Grants/Research Funding); Schering-Plough Corporation – I(Grants/Research Funding), SP(OB); Shire – A(H), I(Grants/Research Funding); Stiefel a GSK company – SP(H); XOMA (US) LLC – I(Grants/Research Funding);
  • Werth, Victoria P., MD: Biogen – C(H), I(Grants/Research Funding); BMS – C(H); Celgene Corporation – C(H), I(Grants/Research Funding); Cipher Pharmaceuticals – C(H); CSL – C(H); Genentech, Inc. – C(H); Gilead Sciences – C(H), I(Grants/Research Funding); Idera Pharmaceuticals, Inc. – C(H); Immune Pharmaceuticals – C(H); Immunotherapeutics – C(H); Janssen Pharmaceuticals, Inc – C(H), I(Grants/Research Funding); Lilly ICOS LLC – C(H); Lupus Foundation of America – C(H); Mallinckrodt Pharmaceuticals – C(H); Medimmune – C(H); Neovacs – C(H); Octapharma – C(H); Pfizer Inc. – C(H), I(Grants/Research Funding); Principia Biopharma Inc. – C(H); Resolve Therapeutics – C(H); Roche Laboratories – C(H); Stiefel a GSK company – C(H); Syntimmune, Inc. – C(H), I(Grants/Research Funding); UV Therapeutics – A(ST);
Schedule
Sunday, February 18
3:30 PM
Dr. Blauvelt / Biologics in atopic dermatitis
4:00 PM
Dr. Murrell / Rituximab in pemphigus vulgaris
4:30 PM
Dr. Werth / Biologics in rheumatologic disorders
5:00 PM
Dr. Kerdel / Hidradenitis Suppurativa: Biologic Therapy
Event Details
  • Date
    Sunday, February 18
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 2
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Francisco Kerdel, MD, FAAD
Speakers
  • Andrew Blauvelt, MD, FAAD
  • Dedee F. Murrell, MD, FAAD
  • Victoria P. Werth, MD, FAAD